Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acipimox lipid-lowering effects on cardiac and skeletal muscle mitochondrial function
NL-OMON35239Active, not recruiting
- Sponsor
- Center for Translational Molecular Medicine (CTMM)
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of acipimox in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Center for Translational Molecular Medicine (CTMM). Primary endpoints: Change in mitochondrial function, Change in lipid accumulation and 1 more. Started Mar 2010; status: active, not recruiting.
02
Drugs
acipimox
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON35239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35239.